.Attributes Medication, Published online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antibody-- drug conjugate (ADC) tisotumab vedotin led to boosted progression-free and total survival, causing FDA approval as well as a brand-new therapy possibility for clients.